Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T11:56:54.387Z Has data issue: false hasContentIssue false
  • English
  • Français

Making Headway—New Treatments in Parkinson's Disease

Published online by Cambridge University Press:  07 November 2014

Mark Stacy  and
Jau-Shin Lou
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Introduction
Information
CNS Spectrums , Volume 3 , Issue 2: Pathophysiologic and Clinical Progress in Parkinson's Disease , February 1998 , pp. 22
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Shannon, KM, Bennett, JP Jr, Friedman, JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology. 1997;49:724–728.CrossRefGoogle ScholarPubMed
2.Lieberman, A, Ranhosky, A, Korts, D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162–168.Google Scholar
3.Adler, CH, Sethi, KD, Hauser, RA, et al.Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997;49:393–399.Google Scholar
4.Rascol, O, Lees, AJ, Senard, JM, Pirtosek, Z, Montastrue, JL, Fuell, D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol. 1996;19:234–245.Google Scholar